GGrantIndex
← Leaderboards

Marialourdes G Tansey

University Of Texas Sw Med Ctr/Dallas

$9,439,468
Attributed
$14,777,736
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.2M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,777,736 · 12

By mechanism

RF1$7,382,782 · 3
R01$5,899,118 · 4
R21$820,738 · 2
R43$350,000 · 1
R25$308,263 · 1
R13$16,835 · 1

Top collaborators

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Inflammatory

Research focus

InflammatoryInflammationNeuroinflammationBrainNeurodegenerative DisordersNerve DegenerationParkinson DiseaseBasePreventResponseMicrogliaCellsPathogenesisMolecularSignal TransductionPublic Health RelevanceMacrophageAffectDisease ProgressionPathway InteractionsProteinsFunctional DisorderChronicNeurons

Grant awards (29)

Role of central and peripheral immune crosstalk in FTD-Grn neurodegeneration$782,364
R01 · FY2025 · NS · contact PI
Role of central and peripheral immune crosstalk in FTD-Grn neurodegeneration$2,446,942
RF1 · FY2022 · NS · contact PI
Proteins, Pathway, and Pathophysiology in Parkinson's Disease: a Gordon Research Conference$16,835
R13 · FY2022 · NS · contact PI
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$337,067
R01 · FY2019 · NS
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$337,363
R01 · FY2018 · NS · contact PI
Emory Initiative to Maximize Student Development$308,263
R25 · FY2018 · GM
Role of Gut Inflammation and Immunity on Proteostasis, Noradrenergic Degeneration and AD risk$932,084
RF1 · FY2017 · AG · contact PI
Role of Gut Inflammation and Immunity on Proteostasis, Noradrenergic Degeneration and AD risk$651,519
RF1 · FY2017 · AG · contact PI
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$336,681
R01 · FY2017 · NS · contact PI
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$50,000
R01 · FY2017 · NS · contact PI
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$2,187
R01 · FY2017 · NS · contact PI
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$336,925
R01 · FY2016 · NS · contact PI
Inflammation and Renin-Angiotensin System Dysfunction as risk factors for AD$3,352,237
RF1 · FY2015 · AG
Role of HLA/MHCII in Parkinson's Disease Pathogenesis$350,149
R01 · FY2015 · NS · contact PI
Novel Dominant Negative TNF Inhibitors for Treatment of Depression$350,000
R43 · FY2015 · MH
Immunophenotyping of LRRK2 mutation carriers$195,000
R21 · FY2015 · NS · contact PI
RGS10 in microglia activation and dopaminergic neuron survival$328,957
R01 · FY2014 · NS · contact PI
Immunophenotyping of LRRK2 mutation carriers$234,000
R21 · FY2014 · NS · contact PI
RGS10 in microglia activation and dopaminergic neuron survival$320,652
R01 · FY2013 · NS · contact PI
RGS10 in microglia activation and dopaminergic neuron survival$332,281
R01 · FY2012 · NS · contact PI
RGS10 in microglia activation and dopaminergic neuron survival$332,281
R01 · FY2011 · NS · contact PI
RGS10 in microglia activation and dopaminergic neuron survival$339,063
R01 · FY2010 · NS · contact PI
TNF Signaling in Neurodegeneration$335,250
R01 · FY2010 · NS · contact PI
TNF Signaling in Neurodegeneration$338,636
R01 · FY2009 · NS · contact PI
TNF Signaling in Neurodegeneration$343,006
R01 · FY2008 · NS · contact PI
TNF Signaling in Neurodegeneration$343,006
R01 · FY2007 · NS · contact PI
TNF Signaling in Neurodegeneration$353,250
R01 · FY2006 · NS · contact PI
Neurogenic Potential of Progenitor Cells in Adipose$211,363
R21 · FY2006 · NS · contact PI
Neurogenic Potential of Progenitor Cells in Adipose$180,375
R21 · FY2005 · NS